Anti-SLC34A2 / anti-4-1BB antibodies and their uses

By developing a multispecific antibody that binds to SLC34A2 and 4-1BB, the lack of existing cancer treatments targeting these two targets was addressed, enabling targeted therapy of cancer cells and activation of immune cells, demonstrating significant anti-tumor effects.

CN123125233APending Publication Date: 2026-11-17LANOVA MEDICINES LTD CO
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
CN202480088149.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-21
Filing Date
2024-12-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the existing technology, the specificity of SLC34A2 and 4-1BB expressed on cancer cells and immune cells has not been effectively utilized, and there is a lack of multispecific antibodies targeting these two targets for cancer treatment.

Method used

Multispecific antibodies were developed that specifically bind to human SLC34A2 and 4-1BB proteins, and the Fc domain was modified to reduce or eliminate effector function for cancer treatment.

Benefits of technology

It achieves targeted therapy of cancer cells, activates 4-1BB signaling, enhances the anti-cancer activity of immune cells, and shows significant anti-tumor efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

Bispecific and multispecific antibodies targeting tumor antigens and 4-1BB are provided, particularly multispecific antibodies with binding specificity to human SLC34A2 and human 4-1BB proteins. Methods for treating cancer using antibodies or their antigen-binding fragments are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Cross-references to related applications

[0001] This application claims the benefit of International Application No. PCT / CN2023 / 140639, filed on December 21, 2023, the contents of which are incorporated herein by reference in their entirety.

[0002] Reference for electronic sequence listing The contents of the electronic serial list (371465.xml; size: 16,805 bytes; creation date: December 19, 2024) are incorporated herein by reference in full. Background Technology

[0003] Compared to neighboring normal cells, cell membrane transport proteins (such as those belonging to the glucose transporter GLUT, ATP-binding cassette transporters ABC, and solute carrier transporters SLC) are frequently upregulated in cancer cells. High levels of these transporters have been found in various solid tumors and are associated with low survival rates. One potential molecular tumor marker could be the sodium-dependent phosphate transporter NaPi2b, encoded by the SLC34A2 (solute carrier 34 A2) gene.

[0004] SLC34A2 encodes a type II Na / Pi cotransporter (NaPi2b), a multi-transmembrane sodium-dependent phosphate transporter responsible for the transcellular uptake of inorganic phosphate. NaPi2b is highly abundant in the brush border membrane of the small intestine, where it participates in the transcellular flow of inorganic phosphate across the apical membrane of epithelial cells. The expression of the sodium-dependent phosphate transporter NaPi2b has been reported to be altered in ovarian cancer, lung cancer, gastric cancer, thyroid cancer, and other cancers.

[0005] 4-1BB (CD137 and TNFRSF9) was first identified as an inducible costimulatory receptor expressed on activated T cells and is a transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) receptor superfamily. Current understanding of 4-1BB indicates that its expression is generally activation-dependent and encompasses a wide range of immune cell subsets, including activated NK cells and NKT cells, regulatory T cells, dendritic cells (DCs) (including follicular DCs), stimulated mast cells, differentiated myeloid cells, monocytes, neutrophils, eosinophils, and activated B cells. Expression of 4-1BB in tumor vascular systems and atherosclerotic endothelium has also been confirmed. The ligand stimulating 4-1BB (4-1BBL) is expressed on activated antigen-presenting cells (APCs), bone marrow progenitor cells, and hematopoietic stem cells.

[0006] Upon B cell receptor binding, the interaction between 4-1BB and its ligand on activated normal human B cells stimulates proliferation and enhances survival. 4-1BB is undetectable on the surface of naive T cells, but its expression increases upon activation. Following 4-1BB activation, TRAF1 and TRAF2, pro-survival members of the TNFR-associated factor (TRAF) family, are recruited to the cytoplasmic tail of 4-1BB, thereby activating downstream NF-κB and mitogen-activated protein (MAP) kinase cascades, including Erk, ink, and p38 MAP kinases.

[0007] Cancer cell-specific expression of SLC34A2 and immune cell expression of 4-1BB suggest that these two targets could be potential cancer targets for antibody therapy. Summary of the Invention

[0008] This disclosure provides multispecific antibodies with binding specificity to human SLC34A2 and 4-1BB proteins. These antibodies and fragments can be used to treat diseases and conditions such as cancer. In some embodiments, the multispecific antibody further comprises an Fc domain having a reduced or eliminated effector function. In some embodiments, the second antibody portion is an sdAb.

[0009] One embodiment of this disclosure provides a multispecific antibody comprising: (1) a first antibody moiety that specifically binds to human lysosome carrier 34A2 (SLC34A2) protein, and (2) a second antibody moiety that specifically binds to human 4-1BB protein. In some embodiments, the multispecific antibody further comprises an Fc domain. In some embodiments, the Fc domain is modified to reduce or eliminate effector function.

[0010] In some embodiments, the first antibody portion or the second antibody portion is F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, or sdAb. In some embodiments, the first antibody portion is Fab'. In some embodiments, the second antibody portion is sdAb. In some embodiments, the Fc domain is derived from any one of the group consisting of IgG1, IgG2, IgG3, and IgG4. In some embodiments, the Fc domain is derived from IgG1.

[0011] In some embodiments, the first antibody portion is a Fab' fused to the N-terminus of the Fc domain, and the second antibody portion is an sdAb fused to the C-terminus of the Fc domain. In some embodiments, the second antibody portion is fused to the Fc domain via a linker.

[0012] In some embodiments, the second antibody moiety comprises HCDR1 containing the amino acid SSAMS (SEQ ID NO: 34), HCDR2 containing the amino acid GIYSGGSTYYTESVKD (SEQ ID NO: 35), and HCDR3 containing the amino acid WGTLRFGVWAEYDH (SEQ ID NO: 36). In some embodiments, the second antibody moiety comprises the amino acid sequence of SEQ ID NO: 9 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 9.

[0013] In some embodiments, the first antibody portion comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising heavy chain complementarity-determining regions HCDR1, HCDR2, and HCDR3, and the light chain variable region comprising heavy chain complementarity-determining regions LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each comprise an amino acid sequence selected from the group consisting of: (a) HCDR1: TNNMH (SEQ ID NO: 10), HCDR2: AIYPGSGATAYNQKFKG (SEQ ID NO: 11), HCDR3: GMYGHGAMDY (SEQ ID NO: 12), LCDR1: KASQDVGTAVA (SEQ ID NO: 13), LCDR2: WATTRHS (SEQ ID NO: 14), and LCDR3: QQYSSNPLT (SEQ ID NO: 15); (b) HCDR1: SYITH (SEQ ID NO: 15). 16), HCDR2: AIYPGNADTSYIQKFKG (SEQ ID NO: 17), HCDR3: GTYGTSAWFTY (SEQ ID NO: 18), LCDR1: RARQNIGNNLY (SEQ ID NO: 19), LCDR2: YASQSIS (SEQ ID NO: 20), and LCDR3: QQSFSWPLT (SEQ ID NO: 21); (c) HCDR1: TYNMH (SEQ ID NO: 22), HCDR2: AIYPGSGDTSYNQKFKG (SEQ ID NO: 23), HCDR3: STIITTGAVDY (SEQ ID NO: 24), LCDR1: KASQDVGTAVA (SEQ ID NO: 25), LCDR2: WTSTRHT (SEQ ID NO: 26), and LCDR3: QQYSRIPLT (SEQ ID NO: 27); and (d) HCDR1: EYIIH (SEQ ID NO: 28), HCDR2: GIIPNNDVTNYKQNFRG (SEQ ID NO: 29), HCDR3: WRNAYYSAMDS (SEQ ID NO: 30), LCDR1: TASQDVGTAVA (SEQ ID NO: 31), LCDR2: WASTRHT (SEQ ID NO: 32), and LCDR3: QQYRTSPLT (SEQ ID NO: 33).

[0014] In some embodiments, the first antibody portion comprises: (a) a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprising the amino acid sequence of SEQ ID NO: 2 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 2; (b) a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 3, and the light chain variable region comprising the amino acid sequence of SEQ ID NO: 4 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 4; (c) a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 5 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 5, and the light chain variable region comprising the amino acid sequence of SEQ ID NO: 6 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 5. A peptide having at least 90% sequence identity with the amino acid sequence of NO: 6; or (d) a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 8.

[0015] In some embodiments, a polynucleotide encoding the antibody or fragment is also provided, as well as a composition comprising the antibody or a fragment thereof and a pharmaceutically acceptable carrier.

[0016] Methods and uses for treating diseases and conditions are also provided. In one embodiment, a method for treating cancer in a patient in need is provided, comprising administering the antibody or a fragment thereof of this disclosure to the patient. Attached Figure Description

[0017] Figure 1 A schematic diagram of the anti-SLC34A2-4-1BB bispecific antibody is shown.

[0018] Figure 2 The results show that all bispecific antibodies bind to CHO-K1 cells overexpressing human 4-1BB in a concentration-dependent manner.

[0019] Figure 3 The results show that all bispecific antibodies bind to HEK293 cells overexpressing SLC34A2 in a concentration-dependent manner.

[0020] Figure 4 This demonstrates that in the presence of HEK293 overexpressing SLC34A2, all bispecific antibodies activate SLC34A2-dependent 4-1BB signaling in a concentration-dependent manner.

[0021] Figure 5 The lead bispecific antibody 30H9-263-1-3-1 demonstrated concentration-dependent binding activity to human and cynomolgus monkey 4-1BB, but no cross-reactivity to mouse 4-1BB.

[0022] Figure 6 The lead bispecific antibody 30H9-263-1-3-1 was shown to exhibit similar binding activity to SLC34A2 from different species, including humans, cynomolgus monkeys, rhesus monkeys, rats, and mice.

[0023] Figure 7 The bispecific antibody 30H9-263-1-3-1 was shown to effectively bind to OVCAR3 and HCC4006 with endogenous SLC34A2 expression.

[0024] Figure 8 The results showed that 30H9-263-1-3-1 induced significant 4-1BB activation in the presence of target cells expressing SLC34A2.

[0025] Figure 9 This study demonstrated that, in the presence of target cells expressing SLC34A2, the bispecific antibody 30H9-263-1-3-1 induced significant IL-2 and IFN-γ production in primary PBMCs. .

[0026] Figure 10 The bispecific antibody 30H9-263-1-3-1 was shown to exhibit strong antitumor efficacy in a human 4-1BB transgenic mouse tumor model. Detailed Implementation

[0027] definition It should be noted that the term "a" or "an" entity refers to one or more entities within that entity; for example, "antibody" should be understood to represent one or more antibodies. Therefore, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably in this document.

[0028] As used herein, the term "polypeptide" is intended to include both the singular and plural forms of "polypeptide" and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any one or more chains of two or more amino acids and does not refer to a specific length of the product. Therefore, peptide, dipeptide, tripeptide, oligopeptide, "protein," "amino acid chain," or any other term used to refer to one or more chains of two or more amino acids is included within the definition of "polypeptide," and the term "polypeptide" may be used in place of or interchangeably with any of these terms. The term "polypeptide" also refers to products of post-expression modifications, including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, lysosomal cleavage, or modification by non-naturally occurring amino acids. Polypeptides may be derived from natural biological sources or produced through recombinant technologies, but are not necessarily translated from a specified nucleic acid sequence. They can be produced in any manner, including through chemical synthesis.

[0029] "Homology," "identity," or "similarity" refers to the sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing positions in each sequence that can be compared for comparative purposes. When a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences varies with the number of matching or homologous positions shared by the sequences. An "irrelevant" or "non-homologous" sequence has less than 40% identity with one of the sequences in this disclosure, but preferably less than 25% identity.

[0030] "Sequence identity" of a polynucleotide or polynucleotide region (or polypeptide or polypeptide region) with another sequence at a certain percentage (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) means that when the two sequences are compared, that percentage of bases (or amino acids) are the same.

[0031] The term "equivalent nucleic acid or polynucleotide" refers to a nucleic acid having a nucleotide sequence that shares a degree of homology or sequence identity with the nucleotide sequence of that nucleic acid or its complement. Homologs of double-stranded nucleic acids are intended to include nucleic acids having a nucleotide sequence that shares a degree of homology with it or its complement. In one respect, a homolog of a nucleic acid is capable of hybridizing with a nucleic acid or its complement. Similarly, "equivalent polypeptide" refers to a polypeptide that shares a degree of homology or sequence identity with the amino acid sequence of a reference polypeptide. In some respects, the sequence identity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%. In some respects, the equivalent polypeptide or polynucleotide has one, two, three, four, or five additions, deletions, substitutions, and combinations thereof compared to the reference polypeptide or polynucleotide. In some respects, the equivalent sequence retains the activity (e.g., epitope binding) or structure (e.g., salt bridge) of the reference sequence.

[0032] As used herein, "antibody" or "antigen-binding polypeptide" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen. An antibody can be a complete antibody or any antigen-binding fragment or single chain thereof. Therefore, the term "antibody" includes any protein or peptide containing a molecule that comprises at least a portion of an immunoglobulin molecule having biological activity of binding to an antigen. Such examples include, but are not limited to, the complementarity-determining region (CDR) or ligand-binding portion of the heavy or light chain, the variable region of the heavy or light chain, the constant region of the heavy or light chain, the frame (FR) region, or any portion thereof, or at least a portion of the binding protein.

[0033] The terms "single-domain antibody" (sdAb) or "single-variable-domain (SVD) antibody" generally refer to antibodies in which a single variable domain (VH or VL) can confer antigen binding. In other words, a single variable domain can recognize a target antigen without interacting with another variable domain. Examples of single-domain antibodies include those derived from camelids (lambs and camels) and cartilaginous fish (e.g., nurse sharks), as well as those derived from recombinant methods using human and mouse antibodies (Nature (1989) 341:544-546; Dev Comp Immunol (2006) 30:43-56; Trend Biochem Sci (2001) 26:230-235; Trends Biotechnol (2003):21:484-490; WO 2005 / 035572; WO 03 / 035694; Febs Lett (1994) 339:285-290; WO00 / 29004; WO 02 / 051870). When sdAb contains only the heavy chain, it can be used interchangeably with "VHH" or "single-heavy-chain variable domain antibody" or "nanobody".

[0034] As used herein, the term "antibody fragment" or "antigen-binding fragment" refers to a portion of an antibody (e.g., F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc.). Regardless of its structure, an antibody fragment binds to the same antigen recognized by the intact antibody. The term "antibody fragment" includes aptamers, mirror isoforms, and biantibodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein that functions like an antibody by binding to a specific antigen to form a complex.

[0035] The term "Fab" in antibody refers to a monovalent antigen-binding fragment of an antibody, consisting of a single light chain (both the variable and constant regions) bound by disulfide bonds to the variable and first constant regions of a single heavy chain. Fab can be obtained by papain digestion of the antibody at residues proximal to the N-terminus of the disulfide bonds between the heavy chains in the hinge region.

[0036] “Fab” refers to a Fab fragment that includes a portion of the hinge region, which can be obtained by pepsin digestion of an antibody at residues proximal to the C-terminus of the inter-heavy chain disulfide bond in the hinge region, and thus differs from Fab in a few residues (including one or more cysteine ​​residues) in the hinge region.

[0037] "F(ab)2" refers to the dimer of Fab', which contains two light chains and a portion of two heavy chains.

[0038] "Single-chain variable fragment" or "scFv" refers to the variable region (V) of the heavy chain of immunoglobulins. H ) and light chain variable region (V L These are fusion proteins. In some respects, these regions are linked to short linker peptides consisting of 10 to approximately 25 amino acids. The linker can be enriched with glycine for flexibility and with serine or threonine for solubility, and can carry V... H N-terminus and V L The C-terminus is linked, and vice versa. Despite the removal of the constant region and the introduction of a linker, the protein retains the specificity of the original immunoglobulin. ScFv molecules are known in the art and are described, for example, in U.S. Patent 5,892,019.

[0039] Full-length antibodies consist of two heavy chains and two light chains. Variable regions of the light and heavy chains are responsible for antigen binding. These variable domains can be referred to as “VH” and “VL”, respectively. The variable regions in both chains typically contain three highly variable loops called complementarity-determining regions (CDRs) (light chain (LC) CDRs include LC-CDR1, LC-CDR2, and LC-CDR3; heavy chain (HC) CDRs include HC-CDR1, HC-CDR2, and HC-CDR3). The CDR boundaries of the antibody and antigen-binding fragments disclosed herein can be defined or identified according to the conventions of Kabat, Chothia, or Al-Lazikani (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). Three cored reticulum (CDRs) of either the heavy or light chain are inserted between flanking segments called framework regions (FRs), which are more conserved than the CDRs and form a scaffold to support the hypervariable loop. The constant regions of the heavy and light chains do not participate in antigen binding but exhibit various effector functions. Antibodies are classified according to the amino acid sequence of the constant region of the antibody heavy chain. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, characterized by the presence of α, δ, ε, γ, and μ heavy chains, respectively. Several major antibody classes are further subdivided into subclasses (e.g., lgG1 (γ1 heavy chain), lgG2 (γ2 heavy chain), lgG3 (γ3 heavy chain), lgG4 (γ4 heavy chain), lgA1 (α1 heavy chain), or lgA2 (α2 heavy chain)).

[0040] According to this disclosure, modifications of each of these categories and isotypes are readily identifiable to those skilled in the art and therefore fall within the scope of this disclosure. All immunoglobulin classes clearly fall within the scope of this disclosure, and the following discussion will generally pertain to the IgG class of immunoglobulin molecules. With respect to IgG, a standard immunoglobulin molecule comprises two identical light chain polypeptides with a molecular weight of approximately 23,000 Daltons, and two identical heavy chain polypeptides with a molecular weight of 53,000 to 70,000 Daltons. These four chains are typically linked by disulfide bonds in a “Y” configuration, wherein the light chain begins at the opening of the “Y” and extends through the variable region to surround the heavy chain.

[0041] The antibodies, antigen-binding peptides, variants, or derivatives thereof disclosed herein include, but are not limited to, polyclonal antibodies, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, primate-derived antibodies, or chimeric antibodies, single-chain antibodies, epitope-binding fragments (e.g., Fab, Fab', and F(ab')2, Fd, Fv, single-chain Fv (scFv)), single-chain antibodies, disulfide-linked Fv (sdFv), fragments containing VK or VH domains, fragments generated from Fab expression libraries, and anti-idiotype (anti-Id) antibodies (including, for example, anti-Id antibodies against the LIGHT antibodies disclosed herein). The immunoglobulin or antibody molecules disclosed herein can be any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecules.

[0042] Light chains are classified as or Each heavy chain class can bind to either a κ or λ light chain. Typically, when immunoglobulins are produced by hybridomas, B cells, or genetically engineered host cells, the light and heavy chains are covalently linked, and the "tail" portions of the two heavy chains are linked together via covalent disulfide bonds or non-covalent bonds. In the heavy chain, the amino acid sequence extends from the N-terminus of the Y-configuration to the C-terminus at the bottom of each chain.

[0043] Both light and heavy chains are divided into structural homologous regions and functional homologous regions. The terms "constant" and "variable" are used according to function. In this regard, it should be understood that the variable domains (VK) of the light chain and the variable domains (VH) of the heavy chain partially determine antigen recognition and specificity. Conversely, the constant domains (CK) of the light chain and the constant domains (CH1, CH2, or CH3) of the heavy chain confer important biological properties (e.g., secretion, transplacental migration, Fc receptor binding, complement binding, etc.). By convention, the numbering of constant domains increases with their distance from the antigen-binding site or N-terminus of the antibody. The N-terminal portion is the variable region, and the C-terminal portion is the constant region; the CH3 and CK domains actually contain the carboxyl terms of the heavy and light chains, respectively.

[0044] As shown above, the variable region allows antibodies to selectively recognize and specifically bind to epitopes on antigens. That is, subsets of the antibody's VK and VH domains, or complementarity-determining regions (CDRs), combine to form a variable region defining a three-dimensional antigen-binding site. This quaternary antibody structure forms antigen-binding sites at the ends of each arm of the Y. More specifically, the antigen-binding site is defined by three CDRs (i.e., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) on each of the VH and VK chains. In some cases (e.g., for certain immunoglobulin molecules derived from camel species or engineered based on camel immunoglobulins), the complete immunoglobulin molecule may consist only of the heavy chain, without the light chain. See, for example, Hamers-Casterman et al. Nature 363:446-448 (1993).

[0045] In naturally occurring antibodies, the six complementarity-determining regions (CDRs) present in each antigen-binding domain are short, discontinuous amino acid sequences. These sequences are specifically localized to form the antigen-binding domain when the antibody assumes its three-dimensional conformation in an aqueous environment. The remaining amino acids in the antigen-binding domain (called the "framework" region) exhibit less intermolecular variability. The framework region primarily utilizes... - Folded conformation, while CDRs form rings, these rings connect - Folded structure, and in some cases formed - Part of the folded structure. Therefore, the framework region acts as a backbone that positions the CDR in the correct orientation via interchain non-covalent interactions. The antigen-binding domain formed by the positioned CDR defines a surface complementary to an epitope on an immunoreactive antigen. This complementary surface facilitates non-covalent binding of the antibody to its homologous epitope. For any given heavy or light chain variable region, those skilled in the art can readily identify the amino acids containing the CDR and framework region, respectively, as they have been precisely defined (see "Sequences of Proteins of Immunological Interest," Kabat, E et al., US Department of Health and Human Services, (1983); and Chothia and Lesk, J. MoI.Biol ., 196:901-917 (1987)).

[0046] Where two or more definitions exist for terms used and / or accepted in this field, the definitions of terms as used herein are intended to include all such meanings unless explicitly stated otherwise. A specific example is the use of the term “complementarity-determining region” (“CDR”) to describe discontinuous antigen-binding sites found within the variable regions of both heavy-chain and light-chain polypeptides. This specific region has been described in Kabat et al., US Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983) and Chothia et al. J. MoI. Biol References .196:901-917 (1987), the full text of which are incorporated herein by reference. The CDR definition by Kabat and Chothia includes overlap or subsets of amino acid residues when compared with each other. However, the application of any definition of a CDR relating to an antibody or its variants is intended to fall within the scope of the terminology as defined and used herein. The appropriate amino acid residues containing a CDR as defined in each of the foregoing references are listed in the table below for comparison. The exact number of residues containing a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues contain a particular CDR based on the amino acid sequence of the variable region of an antibody.

[0047]

[0048] Kabat et al. also defined a numbering system applicable to the variable domain sequences of any antibody. Those skilled in the art can explicitly assign this “Kabat numbering” system to any variable domain sequence without relying on any experimental data outside of the sequence itself. As used herein, “Kabat numbering” refers to the numbering system proposed by Kabat et al., US Dept. of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983).

[0049] In addition to the table above, the Kabat numbering system describes the CDR regions as follows: CDR-H1 begins at approximately the 31st amino acid (i.e., approximately 9 residues after the first cysteine ​​residue), consists of approximately 5 to 7 amino acids, and ends at the next tryptophan residue. CDR-H2 begins at the 15th residue after the end of CDR-H1, consists of approximately 16 to 19 amino acids, and ends at the next arginine or lysine residue. CDR-H3 begins at approximately the 33rd amino acid residue after the end of CDR-H2; consists of 3 to 25 amino acids; and ends at the sequence WGXG, where X is any amino acid. CDR-L1 begins at approximately the 24th residue (i.e., after the cysteine ​​residue); consists of approximately 10 to 17 residues; and ends at the next tryptophan residue. CDR-L2 begins at approximately the 16th residue after the end of CDR-L1 and consists of approximately 7 residues. CDR-L3 begins at approximately the 33rd residue after the end of CDR-L2 (i.e., after the cysteine ​​residue); it consists of approximately 7 to 11 residues and ends at sequence F or WGXG, where X is any amino acid.

[0050] The antibodies disclosed herein can be derived from any animal source, including birds and mammals. Preferably, the antibodies are human, mouse, donkey, rabbit, goat, guinea pig, camel, llama, horse, or chicken antibodies. In another embodiment, the variable region can be derived from condricthoids (e.g., from sharks).

[0051] As used herein, the term "heavy chain constant region" includes an amino acid sequence derived from the immunoglobulin heavy chain. A polypeptide containing a heavy chain constant region comprises at least one of the following: a CH1 domain, a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or variants or fragments thereof. For example, an antigen-binding polypeptide for use in this disclosure may comprise: a polypeptide chain containing a CH1 domain; a polypeptide chain containing at least a portion of a CH1 domain, a hinge domain, and a CH2 domain; a polypeptide chain containing both a CH1 domain and a CH3 domain; a polypeptide chain containing at least a portion of a CH1 domain, a hinge domain, and a CH3 domain; or a polypeptide chain containing at least a portion of a CH1 domain, a hinge domain, a CH2 domain, and a CH3 domain. In another embodiment, the polypeptide of this disclosure comprises a polypeptide chain containing a CH3 domain. Furthermore, antibodies for use in this disclosure may lack at least a portion of the CH2 domain (e.g., all or part of the CH2 domain). As described above, those skilled in the art will understand that the heavy chain constant regions can be modified to differ in amino acid sequence from naturally occurring immunoglobulin molecules.

[0052] The heavy chain constant regions of antibodies disclosed in this paper can be derived from different immunoglobulin molecules. For example, the heavy chain constant regions of peptides can contain components derived from IgG. l The molecule contains the CH1 domain and a hinge region derived from the IgG3 molecule. In another example, the heavy chain constant region may contain a portion derived from IgG. l The heavy chain portion is derived from the hinge region of the IgG3 molecule. In another example, the heavy chain portion may contain components derived from IgG. l Molecules and chimeric hinges derived from IgG4 molecules.

[0053] As used herein, the term "light chain constant region" includes an amino acid sequence derived from the antibody light chain. Preferably, the light chain constant region comprises at least one of a constant κ domain or a constant λ domain.

[0054] A "light chain-heavy chain pair" refers to a combination of light and heavy chains that can form a dimer through disulfide bonds between the CL domain of the light chain and the CH1 domain of the heavy chain.

[0055] As previously described, the subunit structures and three-dimensional conformations of constant regions of various immunoglobulin classes are well known. As used herein, the term "VH domain" includes the amino-terminal variable domain of the immunoglobulin heavy chain, and the term "CH1 domain" includes the first (amino-terminal) constant region domain of the immunoglobulin heavy chain. The CH1 domain is adjacent to the VH domain and is located at the amino terminus of the hinge region of the immunoglobulin heavy chain molecule.

[0056] As used herein, the term "CH2 domain" encompasses the heavy chain portion of an antibody, extending from approximately residue 244 to residue 360 ​​using conventional numbering schemes (residues 244 to 360, Kabat numbering system; residues 231 to 340, EU numbering system; see Kabat et al., US Dept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983). The CH2 domain is unique in that it does not pair tightly with another domain. Instead, two N-linked branched glycan chains are inserted between the two CH2 domains of the intact native IgG molecule. The CH3 domain is also well-documented, extending from the CH2 domain of the IgG molecule to the C-terminus and containing approximately 108 residues.

[0057] As used herein, the term "hinge region" refers to the portion of the heavy chain molecule that connects the CH1 and CH2 domains. This hinge region contains approximately 25 residues and is flexible, allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be further subdivided into three distinct domains: the upper, middle, and lower hinge domains (Roux et al., J. Immunol 161:4083 (1998)).

[0058] The terms “Fc region,” “Fc domain,” or “fragment crystallizable region” used herein are used to define the C-terminal region of the immunoglobulin heavy chain, including the native sequence Fc region and variant Fc regions. Although the boundaries of the Fc region of the immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is generally defined as extending from the amino acid residue at Cys226 or from Pro230 to its carboxyl terminus. The C-terminal lysine of the Fc region (residue 447 according to the EU numbering system) can be removed, for example, during antibody production or purification, or by recombinantly engineering the nucleic acid encoding the antibody heavy chain. Therefore, compositions of complete antibodies may include the following antibody populations: antibody populations with all K447 residues removed, antibody populations with K447 residues not removed, and antibody populations having mixtures of antibodies containing and without K447 residues. Suitable native sequence Fc regions for the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4.

[0059] As used herein, the term "disulfide bond" refers to a covalent bond formed between two sulfur atoms. The amino acid cysteine ​​contains a thiol group that can form a disulfide bond or bridge with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CK regions are linked by disulfide bonds, and the two heavy chains are linked by two disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (positions 226 or 229, EU numbering system).

[0060] As used herein, the term "chimeric antibody" will be understood to refer to any antibody in which the immune-reactive region or site is derived from or originates from a first species and the constant region (which, according to this disclosure, may be whole, partial, or modified) is derived from a second species. In some embodiments, the target-binding region or site will be derived from a non-human source (e.g., mouse or primate), and the constant region will be human.

[0061] The term “humanized antibody” is used herein to describe an antibody comprising heavy and light chain variable region sequences derived from a non-human species (e.g., mouse), but wherein at least a portion of the VH and / or VL sequences has been altered to be more “human-like,” i.e., more similar to human germline variable sequences. A “humanized antibody” is an antibody or a variant, derivative, analog, or fragment thereof that binds to a target antigen with immune specificity and comprises a frame (FR) region having substantially the amino acid sequence of a human antibody and a complementarity-determining region (CDR) having substantially the amino acid sequence of a non-human antibody. As used herein, in the context of CDR, the term “substantially” means a CDR having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% of the same amino acid sequence as the CDR of a non-human antibody. Humanized antibodies comprise substantially all of at least one, typically two, variable domains (Fab, Fab', F(ab')2, Fv), wherein all or substantially all of the CDR regions correspond to the CDR regions of non-human immunoglobulins (i.e., donor antibodies), and all or substantially all of the frame regions are frame regions of the human immunoglobulin common sequence. In one embodiment, the humanized antibody further comprises at least a portion of the immunoglobulin constant region (Fc), typically at least a portion of the constant region of a human immunoglobulin. In some embodiments, the humanized antibody comprises at least a variable domain of the light chain and the heavy chain. The antibody may also comprise CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain. In some embodiments, the humanized antibody comprises only the humanized light chain. In some embodiments, the humanized antibody comprises only the humanized heavy chain. In a specific embodiment, the humanized antibody comprises only the humanized variable domains of the light chain and / or the humanized heavy chain.

[0062] As used herein, the term "epitope" refers to a specific set of atoms or amino acids on an antigen that bind to an antibody or antibody moiety. If two antibodies or antibody moiety exhibit competitive binding to an antigen, they can bind to the same epitope within the antigen.

[0063] As used in this paper, the "percentage of humanization" is calculated by subtracting the number of framework amino acid differences (i.e., non-CDR differences) between the humanized domain and the germline domain from the total number of amino acids, then dividing by the total number of amino acids and multiplying by 100.

[0064] "Specific binding" or "specific to" generally refers to an antibody binding to an epitope via its antigen-binding domain, and this binding requires some complementarity between the antigen-binding domain and the epitope. According to this definition, an antibody is considered to "specifically bind" to an epitope when it binds to that epitope more readily than to a random, unrelated epitope. The term "specific" is used herein to define the relative affinity of an antibody for a given epitope. For example, antibody "A" may be considered to have higher specificity for a given epitope than antibody "B," or antibody "A" may be considered to bind to epitope "C" with higher specificity than it binds to related epitope "D."

[0065] As used herein, the term “treatment” refers to both therapeutic treatment and preventative or defensive measures aimed at preventing or mitigating (alleviating) undesirable physiological changes or conditions (such as cancer progression). Beneficial or desired clinical outcomes include, but are not limited to, reduction of detectable or undetectable symptoms, reduction of disease severity, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or mitigation of the disease state, and (partial or complete) remission. “Treatment” can also mean extended survival compared to expected survival without treatment. Conditions requiring treatment include those already having a condition or symptom, those susceptible to a condition or symptom, or those requiring prevention of a condition or symptom.

[0066] "Subject" or "individual" or "animal" or "patient" or "mammal" means any subject on whom a diagnosis, prognosis or treatment is expected, particularly a mammalian subject. Mammal subjects include humans, livestock, farm animals, as well as zoo animals, sporting animals or pet animals (e.g., dogs, cats, guinea pigs, rabbits, rats, mice, horses, cows, dairy cows, etc.).

[0067] As used herein, phrases such as “patient in need of treatment” or “subject in need of treatment” include subjects (e.g., mammalian subjects) who will benefit from administration of the antibody or composition disclosed herein for, for example, detection, diagnostic procedures and / or treatment.

[0068] Anti-SLC34A2 antibody portion This disclosure provides a multispecific antibody containing one or more antigen-binding moieties that have binding specificity to the human SLC34A2 protein. Clones 30H9, 62G10, 63A11, and 91C9 were selected for constructing the multispecific antibody.

[0069] According to one embodiment of this disclosure, an antigen-binding moiety is provided, comprising heavy chain and light chain variable domains having CDR regions. The CDRs are summarized in Table A1 below (Kabat numbers).

[0070] Table A1. CDR sequence of anti-SLC34A2 antibody

[0071] The variable areas are summarized in Table A2 below.

[0072] Table A2. Variable region sequence of the anti-SLC34A2 antigen-binding region

[0073] In some embodiments, VH CDR1, CDR2, and CDR3 are selected from any group of VH CDR1, CDR2, and CDR3 shown in Table 1, and VL CDR1, CDR2, and CDR3 are selected from any group of VL CDR1, CDR2, and CDR3 shown in Table 1. In some embodiments, VH CDR1, CDR2, and CDR3, as well as VL CDR1, CDR2, and CDR3, are selected from those derived from the same antigen-binding moiety.

[0074] In some embodiments, at least one, two, three, four, five, or six of the above-mentioned VH CDR1, CDR2, and CDR3 and VL CDR1, CDR2, and CDR3 are modified by the addition, deletion, substitution, or combination thereof of one, two, or three amino acids.

[0075] Depending on the specific implementation, the antibody is humanized. Humanized forms of non-human (e.g., mouse) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding sequence of the antibody) containing a minimal sequence derived from a non-human immunoglobulin. Humanized antibodies include human immunoglobulins (receptor antibodies) in which residues forming the complementarity-determining region (CDR) of the receptor are replaced by residues from a CDR of a non-human species (donor antibody) (e.g., mouse, rat, or rabbit) possessing the desired specificity, affinity, and capability. In some cases, Fv framework residues of human immunoglobulins are replaced by corresponding non-human residues. Humanized antibodies may also contain residues that are not present in the receptor antibody or in the introduced CDR or framework sequence. Typically, humanized antibodies will contain substantially all of at least one, usually two, variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of non-human immunoglobulins, and all or substantially all of the FR regions are FR regions of the human immunoglobulin common sequence. Humanized antibodies preferably also contain at least a portion of the immunoglobulin constant region (Fc), typically at least a portion of the human immunoglobulin constant region (Jones et al., Nature, 321: 522-525 (1986); Riechmann et al., Nature, 332: 323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992)).

[0076] Methods for humanizing nonhuman antibodies are well known in the art. Typically, one or more amino acid residues from a nonhuman source are introduced into the humanized antibody. These nonhuman amino acid residues are generally referred to as importing residues, and these residues are typically derived from the importing variable domain. Humanization can be performed essentially as Winter et al. (Jones et al., Nature, 321: 522-525 (1986); Riechmann et al., Nature 332: 323-327 (1988); Verhoeyen et al., Science, 239: 1534-1536 (1988)) by replacing the corresponding sequence of the human antibody with a rodent CDR or CDR sequence. Thus, such humanized antibodies are chimeric antibodies (US Patent No. 4,816,567), in which substantially less than the complete human variable domain is replaced by a corresponding sequence from a nonhuman species. In practice, humanized antibodies are often human antibodies in which some CDR residues and possibly some FR residues are replaced with residues from similar sites in rodent antibodies.

[0077] In some embodiments, the antibody and its antigen-binding fragment are humanized and contain a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, or a peptide having at least 90%, at least 95%, or at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 1.

[0078] In some embodiments, the antibody and its antigen-binding fragment are humanized and contain a light chain variable region comprising the amino acid sequence of SEQ ID NO: 3 or a peptide having at least 90%, at least 95%, or at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 3.

[0079] In some embodiments, the antibody and its antigen-binding fragment are humanized and include a heavy chain variable region and a light chain variable region, the heavy chain variable region containing the amino acid sequence of SEQ ID NO: 5 and the light chain variable region containing the amino acid sequence of SEQ ID NO: 5.

[0080] In some embodiments, the antibody and its antigen-binding fragment are humanized and contain a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 or a peptide having at least 90%, at least 95%, or at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 7.

[0081] In some embodiments, the antibody and its antigen-binding fragment are humanized and contain a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2 or a peptide having at least 90%, at least 95%, or at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 2.

[0082] In some embodiments, the antibody and its antigen-binding fragment are humanized and contain a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4 or a peptide having at least 90%, at least 95%, or at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 4.

[0083] In some embodiments, the antibody and its antigen-binding fragment are humanized and contain a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6 or a peptide having at least 90%, at least 95%, or at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 6.

[0084] In some embodiments, the antibody and its antigen-binding fragment are humanized and contain a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8 or a peptide having at least 90%, at least 95%, or at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 8.

[0085] In some embodiments, the antibody and its antigen-binding fragment are humanized and contain a heavy chain variable region and a light chain variable region, the heavy chain variable region containing the amino acid sequence of SEQ ID NO: 1 and the light chain variable region containing the amino acid sequence of SEQ ID NO: 2.

[0086] In some embodiments, the antibody and its antigen-binding fragment are humanized and include a heavy chain variable region and a light chain variable region, the heavy chain variable region containing the amino acid sequence of SEQ ID NO: 3 and the light chain variable region containing the amino acid sequence of SEQ ID NO: 4.

[0087] In some embodiments, the antibody and its antigen-binding fragment are humanized and include a heavy chain variable region and a light chain variable region, the heavy chain variable region containing the amino acid sequence of SEQ ID NO: 5 and the light chain variable region containing the amino acid sequence of SEQ ID NO: 6.

[0088] In some embodiments, the antibody and its antigen-binding fragment are humanized and include a heavy chain variable region and a light chain variable region, the heavy chain variable region containing the amino acid sequence of SEQ ID NO: 7 and the light chain variable region containing the amino acid sequence of SEQ ID NO: 8.

[0089] Anti-4-1BB antibody part This disclosure provides a multispecific antibody containing one or more antigen-binding moieties that have binding specificity to human 4-1BB protein.

[0090] According to one embodiment of this disclosure, an antigen-binding portion is provided, comprising a single-domain antibody (sdAb) having a CDR region. CDRs are summarized in Table B1 below (Kabat numbers). Exemplary single-chain variable domains are shown in Table B2.

[0091] Table B1. CDR sequence of anti-4-1BB antibody

[0092] Table B2. Exemplary single-chain variable domains of anti-4-1BB antibody portions

[0093] It should be understood that CDRs can be modified to include CDRs with one, two, or three amino acid additions, deletions, and / or substitutions. In some embodiments, substitutions can be conservative substitutions.

[0094] In one embodiment, HCDR1 comprises the amino acid sequence of SEQ ID NO: 34, HCDR2 comprises the amino acid sequence of SEQ ID NO: 35, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 36. In some embodiments, VHH / sdAb comprises the amino acid sequence of SEQ ID NO: 9 or a peptide having at least 90% (or at least 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence of SEQ ID NO: 9.

[0095] The CDR, heavy chain variable region, light chain variable region, or single heavy chain variable domain disclosed herein can be further modified. In some embodiments, the modified heavy chain variable region, light chain variable region, or single heavy chain variable domain retains at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity and is still able to bind to the target site.

[0096] In some embodiments, the modification is replaced at no more than one hotspot location per CDR. In some embodiments, the modification is replaced at one, two, or three such hotspot locations. In one embodiment, the modification is replaced at one of the hotspot locations. In some embodiments, such replacement is conservative replacement.

[0097] "Conservative amino acid substitution" is the substitution in which an amino acid residue is replaced by an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains are defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, non-essential amino acid residues in immunoglobulin peptides are preferably replaced by another amino acid residue from the same side chain family. In another embodiment, a string of amino acids can be replaced by a structurally similar string that differs in sequence and / or composition from members of the side chain family.

[0098] The table below provides non-limiting examples of conserved amino acid substitutions, where a similarity score of 0 or higher indicates that there is a conserved substitution between the two amino acids.

[0099] Table C1. Amino acid similarity matrix

[0100] Table C2. Conserved Amino Acid Substitutions

[0101] Those skilled in the art will also understand that the antibodies disclosed herein can be modified to differ in amino acid sequence from the naturally occurring binding polypeptides from which they are derived. For example, the polypeptide or amino acid sequence derived from the specified protein can be similar, for example, having a certain percentage of identity with the starting sequence, such as 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identity with the starting sequence.

[0102] Multispecific antibodies The antibodies described herein are multispecific antibodies (e.g., bispecific antibodies). As used herein, the term "multispecific antibody" refers to an antibody comprising an antigen-binding domain having multi-epitope specificity (i.e., the ability to bind to two or more different epitopes on one molecule, or the ability to bind to epitopes on two or more different molecules). In some embodiments, a multispecific antibody is a monoclonal antibody (e.g., a bispecific antibody) having binding specificity to at least two different antigen-binding sites. In some embodiments, the first antibody domain and the second antibody domain of a multispecific antibody can bind to epitopes located within two different molecules (intermolecular binding).

[0103] In some embodiments, the multispecific antibodies provided herein may be bispecific antibodies. As used herein, the term "bispecific antibody" refers to a multispecific antibody containing antibody domains capable of binding to two different epitopes on one molecule, or capable of binding to epitopes on two different molecules. Bispecific antibodies may also be referred to herein as having "dual specificity" or "dual-specific." Exemplary bispecific antibodies may bind to both SLC34A2 and any other antigen. In some embodiments, one binding specificity targets SLC34A2, and the other binding specificity targets 4-1BB. Bispecific antibodies can also be used to target cytotoxic agents to cells expressing SLC34A2.

[0104] Techniques for preparing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy-light chain pairs with different specificities (see Milstein and Cuello, Nature 305: 537 (1983), WO 93 / 08829, and Traunecker et al., EMBO J. 10: 3655 (1991)), and mortar engineering (see, for example, US Patent Nos. 5,731,168, WO2009 / 089004, US2009 / 0182127, US2011 / 0287009, Marvin and Zhu, Acta Pharmacol. Sin. (2005) 26(6):649-658, and Kontermann (2005) Acta Pharmacol. Sin., 26: 1-9).

[0105] This disclosure provides anti-SLC34A2 antigen-binding moieties and anti-4-1BB antigen-binding moieties as bispecific or multispecific antibodies. (The last sentence appears to be incomplete and possibly refers to a different topic.) Figure 3 ) and anti-4-1BB antibody ( Figure 2 In comparison, the bispecific antibodies presented in this paper exhibited binding activity comparable to human SLC34A2 protein and human 4-1BB protein, respectively, as well as SLC34A2-dependent 4-1BB signaling (…). Figure 4 The bispecific antibody presented in this article also showed specific affinity for monkey 4-1BB protein, but not for mouse 4-1BB protein. Figure 5 It also exhibits specific affinity for SLC34A2 protein in monkeys, rats, and mice. Figure 6 Furthermore, by using bispecific antibodies to target the SLC34A2 antigen, activation of the 4-1BB pathway can be simultaneously induced. Figure 8 ) and T cell activation ( Figure 9 This also demonstrates an effective in vivo anti-tumor effect. Figure 10 ).

[0106] In some embodiments, the anti-SLC34A2 antibody portion provided herein is in the form of a full-length antibody / IgG, F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, or sdAb / VHH / nanobody.

[0107] In some embodiments, the anti-4-1BB antibody portion provided herein is in the form of a full-length antibody / IgG, F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, or sdAb / VHH / nanobody.

[0108] In some embodiments, the anti-SLC34A2 antibody portion provided herein has a Fab' form, and the anti-4-1BB antibody portion provided herein has a single-domain antibody (sdAb).

[0109] In some embodiments, the bispecific antibodies provided herein further comprise an Fc domain. In some embodiments, the anti-SLC34A2 antibody portion is fused to the N-terminus of the Fc domain, and the anti-4-1BB antibody portion is fused to the N-terminus of the anti-SLC34A2 antibody portion. In some embodiments, the anti-SLC34A2 antibody portion is fused to the N-terminus of the Fc domain, and the anti-4-1BB antibody portion is fused to the C-terminus of the Fc domain.

[0110] The Fc region can be engineered to enhance or eliminate effector functions. IgG antibodies can induce direct antitumor effects by generating indirect antitumor effects through Fc-mediated effector functions that bind to other immune cells or killing mechanisms. As used herein, “effector function” or “antibody effector function” refers to the biological activity resulting from the binding of an antibody’s Fc region to its effector (e.g., the C1 complex and Fc receptor (FcγRIIa or FcγRIIIa)). Exemplary effector functions include: complement-dependent cytotoxicity (CDC) induced by the interaction of the antibody with C1q on the C1 complex; antibody-dependent cell-mediated cytotoxicity (ADCC) induced by the binding of the antibody’s Fc region to the Fc receptor on effector cells; and antibody-dependent cell-mediated phagocytosis (ADCP), in which nonspecific cytotoxic cells expressing the Fcγ receptor (FcγR) recognize antibodies bound to target cells, subsequently causing phagocytosis of the target cells.

[0111] Of the four IgG subclasses, IgG1 and IgG3 induce the strongest Fc effector functions. However, due to the longest half-life and greater stability of IgG1 than IgG3, most therapeutic antibodies with Fc-mediated functions are IgG1 isotypes.

[0112] Both IgG2 and IgG4 isoforms exhibit significantly lower binding affinity for FcγR. Recent evidence suggests that the IgG2 isoform is not entirely devoid of effector function, while the IgG4 isoform can undergo in vivo Fab arm exchange, thereby generating bispecific antibodies and triggering off-target effects.

[0113] In some embodiments, the antibody or antigen-binding fragment thereof provided herein is an isotype of IgG1, IgG2, IgG3, or IgG4. In some embodiments, the antibody or antigen-binding fragment thereof is an isotype of IgG1. In some embodiments, the antibody or antigen-binding fragment thereof is human IgG1. In some embodiments, the antibody or antigen-binding fragment thereof is modified IgG1 having reduced or eliminated effector functions.

[0114] In some embodiments, the modified IgG1 comprises N297A modification. In some embodiments, the modified IgG1 comprises the amino acid sequence of SEQ ID NO: 37, or a peptide having at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% sequence identity with the amino acid sequence of SEQ ID NO: 37 (Table D).

[0115] Table D. IgG1 N297A Fc domain sequence

[0116] In some implementations, the anti-4-1BB antibody portion fuses with the Fc domain via a linker.

[0117] The linkers within the scope of this disclosure are characterized in terms of amino acid content, length, rigidity, and secondary structure. The linkers within the scope of this disclosure separate a functional peptide from another functional peptide and allow each domain to fold correctly and function. In this way, the linkers can be tailored for specific functional peptides and other functional peptides. According to one aspect, the functional independence of the structural and fusion (heterologous) domains is maximized by appropriate linkers to limit spatial interference between domains during bacterial cell export and assembly. According to one aspect, longer and more flexible linkers of the type (GGGGS)n (SEQ ID NO: 38), (GGGS)n (SEQ ID NO: 39), or (GGS)n (where n is an integer from 1 to 20) are exemplary. According to another aspect, cellular stress is minimized by limiting the total length of the fusion protein. Longer linker sequences and higher induction levels stress the cellular biosynthetic mechanisms, inhibiting cell growth and leading to cell lysis in extreme cases.

[0118] The linkers within the scope of this disclosure facilitate the function of antibody domains. The linkers within the scope of this disclosure allow for efficient protein processing and export via bacterial coiling secretion mechanisms, and provide appropriate spatial and physicochemical separation of the respective antibody domains to preserve their respective functions.

[0119] The linkers within the scope of this disclosure include amino acid residues. These amino acid residues can be any naturally occurring amino acid residue. They can also be synthetic amino acids known to those skilled in the art. Representative amino acids that can be used as linkers include glycine, alanine, valine, leucine, isoleucine, serine, cysteine, selenocysteine, threonine, methionine, proline, phenylalanine, tyrosine, tryptophan, histidine, lysine, arginine, aspartic acid, glutamic acid, asparagine, and glutamine.

[0120] According to one aspect, when linking antibody domains, the linker length can be any length that can be expressed by cells (e.g., bacterial cells). According to one aspect, the linker sequence is a polypeptide sequence of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 24, 48 or more amino acids.

[0121] In some embodiments, the antibody comprises an amino acid sequence or one or more portions that are not normally associated with the antibody. Exemplary modifications are described in more detail below. For example, the antibodies of this disclosure may comprise a flexible linker sequence or may be modified to add a functional portion (e.g., PEG, a drug, a toxin, or a label).

[0122] The antibodies, variants, or derivatives disclosed herein include modified derivatives, i.e., those obtained by covalently linking any type of molecule to the antibody such that the covalent link does not prevent the antibody from binding to the epitope. For example, but not as a limitation, antibodies can be modified, such as by glycosylation, acetylation, polyethylene glycolation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, or linking to cellular ligands or other proteins. Any of these chemical modifications can be performed using known techniques, including but not limited to specific chemical cleavage, acetylation, formylation, and the metabolic synthesis of tunicamycin. Additionally, antibodies may contain one or more non-classical amino acids.

[0123] Antibodies can be detectably labeled by conjugation to chemiluminescent compounds. The presence of the chemiluminescently labeled antigen-binding peptide is then determined by detecting the presence of light emitted during the chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salts, and oxalates.

[0124] Fluorescent metals (e.g.) can also be used. 152Antibodies can be detectably labeled using eu or other lanthanides. These metals can be attached to antibodies using metal chelating groups such as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). The technique of conjugating various parts with antibodies is well known; see, for example, Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy,” cited in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. (1985); Hellstrom et al., “Antibodies For Drug Delivery,” in Controlled Drug Delivery (2nd edition), Robinson et al. (eds.), Marcel Dekker, Inc., pp. 623-53 (1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review,” in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); “Analysis, Results, and Future Prospective Of The Therapeutic Use Of Radiolabeled "Antibody in Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), Academic Press, pp. 303-16 (1985).

[0125] Polynucleotides encoding antibodies and methods for preparing antibodies This disclosure also provides isolated polynucleotide or nucleic acid molecules encoding antibodies, variants, or derivatives thereof. The polynucleotides of this disclosure may encode the entire heavy and light chain variable regions of an antigen-binding polypeptide, variant, or derivative thereof, either on the same polynucleotide molecule or on different polynucleotide molecules. Additionally, the polynucleotides of this disclosure may encode portions of the heavy and light chain variable regions of an antigen-binding polypeptide, variant, or derivative thereof, either on the same polynucleotide molecule or on different polynucleotide molecules.

[0126] Methods for preparing antibodies are well known in the art and are described herein. In some embodiments, both the variable and constant regions of the antigen-binding polypeptide of this disclosure are fully human. Fully human antibodies can be prepared using techniques described in the art and as described herein. For example, fully human antibodies against a specific antigen can be prepared by administering an antigen to a transgenic animal that has been modified to produce such antibodies in response to antigen challenge, but whose endogenous loci have been deactivated. Exemplary techniques that can be used to prepare such antibodies are described in U.S. Patents 6,150,584, 6,458,592, and 6,420,140, ​​the entire contents of which are incorporated herein by reference.

[0127] Treatment As described herein, the antibodies, variants, or derivatives disclosed herein can be used in certain therapeutic and diagnostic methods.

[0128] This disclosure also relates to antibody-based therapies involving the administration of the antibodies of this disclosure to patients (e.g., animals, mammals, and humans) for the treatment of one or more of the conditions or illnesses described herein. Therapeutic compounds of this disclosure include, but are not limited to, the antibodies of this disclosure (including variants and derivatives thereof as described herein) and nucleic acids or polynucleotides encoding the antibodies of this disclosure (including variants and derivatives thereof as described herein).

[0129] The antibodies disclosed herein can also be used to treat or inhibit cancer. In some embodiments, cancer cells in a patient express or overexpress SLC34A2. As described above, SLC34A2 can be overexpressed in tumor cells, particularly in tumors of the stomach, pancreas, esophagus, ovary, and lung. Inhibition of SLC34A2 has been shown to be useful in the treatment of tumors.

[0130] Therefore, in some embodiments, methods for treating cancer in patients in need are provided. In one embodiment, the method involves administering an effective amount of the disclosed antibody to the patient. In some embodiments, at least one cancer cell (e.g., stromal cells) in the patient overexpresses SLC34A2.

[0131] In some implementations, cells are isolated from the cancer patient themselves. In other implementations, cells are provided by a donor or from a cell bank. When cells are isolated from cancer patients, unwanted immune responses can be minimized.

[0132] Non-limiting examples of cancer include bladder cancer, liver cancer, colon cancer, rectal cancer, endometrial cancer, leukemia, lymphoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, urethral cancer, head and neck cancer, gastrointestinal cancer, stomach cancer, esophageal cancer, ovarian cancer, kidney cancer, melanoma, prostate cancer, and thyroid cancer.

[0133] The antibodies or variants or derivatives thereof disclosed herein can be used to treat, prevent, diagnose, and / or prognose other diseases or conditions associated with increased cell survival, including but not limited to the progression and / or metastasis of malignancies and related conditions such as leukemia (including acute leukemia (e.g., acute lymphoblastic leukemia, acute myeloid leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemia (e.g., chronic myeloid (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphoma (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström macroglobulinemia, heavy chain disease, and solid tumors, including but not limited to sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, and liposarcoma. Sarcoma, chondrosarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangioma, lymphangioendothelial sarcoma, synovoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchial carcinoma, renal cell carcinoma, hepatocellular carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, nephroblastoma, cervical cancer, testicular tumor, lung cancer, small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

[0134] The specific dosage and treatment regimen for any particular patient will depend on a number of factors, including the specific antibody used, its variant or derivative, the patient's age, weight, general health condition, sex and diet, timing of administration, excretion rate, drug combination, and the severity of the specific disease being treated. The healthcare professional's judgment of these factors is within the realm of ordinary technical skill in this art. The dosage will also depend on the individual patient to be treated, the route of administration, the type of formulation, the characteristics of the compound used, the severity of the disease, and the desired effect. The dosage used can be determined using pharmacological and pharmacokinetic principles known in the art.

[0135] Methods of administration for antibodies and variants include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. Antigen-binding peptides or compositions can be administered via any convenient route (e.g., by infusion or bolus, absorption through the epithelial or mucosal skin layer (e.g., oral mucosa, rectal and intestinal mucosa, etc.)) and can be administered together with other bioactive agents. Therefore, pharmaceutical compositions containing the antigen-binding peptides of this disclosure can be administered orally, rectally, parenterally, intracerebrospinal, intravaginally, intraperitoneally, topically (e.g., by powder, ointment, drops, or transdermal patch), sublingually, or as oral or nasal sprays.

[0136] As used in this article, the term "parenteral" refers to administration methods including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, and intra-articular injections and infusions.

[0137] Administration can be systemic or local. Furthermore, it is desirable to introduce the antibodies of this disclosure into the central nervous system via any suitable route, including intraventricular and intrathecal injection; intraventricular injection can be facilitated, for example, by an intraventricular catheter connected to a reservoir (e.g., an Ommaya reservoir). Pulmonary administration can also be employed, for example, by using an inhaler or nebulizer and in combination with a nebulizing agent.

[0138] It is desirable to apply the antigen-binding peptides or compositions of this disclosure topically to the area requiring treatment; this can be achieved, for example, but not limited to, local infusion during surgery, local application (e.g., in conjunction with postoperative wound dressings), by injection, via catheter, via suppository, or via implants that are porous, non-porous, or gel-like materials, including membranes (e.g., sialic acid membranes) or fibers. Preferably, when applying the proteins (including antibodies) of this disclosure, care must be taken to use materials that do not absorb the proteins.

[0139] The amount at which the antibody of this disclosure will effectively treat, inhibit, and prevent immune or malignant diseases, symptoms, or conditions can be determined using standard clinical techniques. Additionally, in vitro assays may optionally be used to help identify the optimal dose range. The precise dose used in the formulation will also depend on the route of administration and the severity of the disease, symptom, or condition, and should be determined based on the physician's judgment and the individual patient's situation. The effective dose can be extrapolated from dose-response curves derived from in vitro or animal model testing systems.

[0140] As a general recommendation, the dosage of the antigen-binding peptide of this disclosure administered to patients is typically 0.1 mg / kg to 100 mg / kg patient body weight, 0.1 mg / kg to 20 mg / kg patient body weight, or 1 mg / kg to 10 mg / kg patient body weight. Generally, due to the immune response to exogenous peptides, human antibodies have a longer half-life in the human body than antibodies from other species. Therefore, lower doses and less frequent administration of human antibodies are generally possible. Furthermore, the dosage and frequency of administration of the antibodies of this disclosure can be reduced by modifications (e.g., lipolysis) that enhance antibody uptake and tissue penetration (e.g., into the brain).

[0141] In another embodiment, the compositions of this disclosure are administered in combination with cytokines. Cytokines that can be administered with the compositions of this disclosure include, but are not limited to, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, anti-CD40, CD40L, and TNF-α. .

[0142] In another embodiment, the compositions disclosed herein are administered in combination with other treatment or preventative measures (e.g., radiotherapy).

[0143] Composition This disclosure also provides pharmaceutical compositions. Such compositions comprise an effective amount of antibody and an acceptable carrier. In some embodiments, the composition further comprises a second anticancer agent (e.g., an immune checkpoint inhibitor).

[0144] In one specific implementation, the term "pharmaceutical acceptable" means a substance approved by a federal or state regulatory agency or listed in the United States Pharmacopeia or other recognized pharmacopoeia for use in animals, and more particularly for human use. Furthermore, "pharmaceutical acceptable carrier" generally refers to any type of non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, or formulation adjuvant.

[0145] The term "carrier" refers to a diluent, adjuvant, excipient, or solvent that is administered with the therapeutic agent. Such drug carriers can be sterile liquids, such as water and oils, including petroleum, animal, plant, or synthetic oils, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Water is the preferred carrier when the drug composition is administered intravenously. Saline solutions, as well as glucose and glycerol solutions, can also be used as liquid carriers, particularly for injectable solutions. Suitable drug excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skim milk powder, glycerin, propylene, ethylene glycol, water, ethanol, etc. If desired, the composition may also contain small amounts of wetting agents or emulsifiers, or pH buffers (e.g., acetates, citrates, or phosphates). Antimicrobial agents (e.g., benzyl alcohol or methylparaben); antioxidants (e.g., ascorbic acid or sodium bisulfite); chelating agents (e.g., EDTA); and agents for regulating tension (e.g., sodium chloride or glucose) may also be considered. These compositions can be in the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, etc. Compositions can be formulated into suppositories using conventional binders and carriers (e.g., triglycerides). Oral formulations may contain standard carriers (e.g., pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, etc.). Examples of suitable drug carriers are described in EW Martin's Remington's Pharmaceutical Sciences, which is incorporated herein by reference. Such compositions will contain a therapeutically effective amount of an antigen-binding polypeptide (preferably in a purified form) and an appropriate amount of carrier to provide a form suitable for appropriate administration to the patient. The formulation should be suitable for the mode of administration. Parenteral formulations may be packaged in ampoules, disposable syringes, or multi-dose vials made of glass or plastic.

[0146] In one embodiment, the composition is formulated according to conventional methods to a pharmaceutical composition suitable for intravenous administration to humans. Typically, the composition for intravenous administration is a solution in a sterile isotonic buffer solution. If necessary, the composition may also contain a solubilizer and a local anesthetic (e.g., lidocaine) to relieve pain at the injection site. These components are typically provided individually or in combination in unit dosage forms, for example, as lyophilized powder or anhydrous concentrate in a sealed container (e.g., an ampoule or sachet) indicating the amount of active agent. When the composition is administered by infusion, it can be dispensed using an infusion bottle containing sterile pharmaceutical-grade water or saline. When the composition is administered by injection, a single ampoule of sterile water or saline for injection can be provided to allow for mixing of the components prior to administration.

[0147] The antibodies disclosed herein can be formulated into neutral or salt forms. Pharmaceutically acceptable salts include salts that form with anions (e.g., salts derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, etc.) and salts that form with cations (e.g., salts derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.).

[0148] Example Example 1: Generation of anti-SLC34A2-4-1BB bispecific antibody The anti-SLC34A2-4-1BB bispecific antibody was designed as a tetravalent IgG (H)-VHH fusion, where the Fc domain is an IgG1 backbone with an N297A mutation to disable Fcγ function. The anti-SLC34A2 portion constitutes the complete IgG unit, while the anti-4-1BB is a VHH located at the C-terminus of the Fc fragment via a G4S linker. The form of the bispecific antibody is shown in [illustration]. Figure 1 The sequences of the previously identified anti-SLC34A2 arm and anti-4-1BB nanobody used to construct bispecific antibodies are shown in Table 1.

[0149] Table 1. VH / VL sequences of the lead bispecific antibody

[0150] The resulting bispecific antibodies were transiently produced in CHO-K1 cells and purified by protein A affinity chromatography. The qualified bispecific antibodies were used for in vitro characterization, including cell-based assays of 4-1BB binding, SLC34A2 binding, and SLC34A2-dependent 4-1BB activation reporter gene activation.

[0151] Based on 4-1BB binding in cells To evaluate the 4-1BB binding activity of the bispecific antibody, CHO-K1 cells overexpressing human 4-1BB were incubated with different concentrations of anti-SLC34A2-4-1BB bispecific antibody at 4°C for 30 minutes. The cells were then washed twice with FACS buffer and stained with PE-conjugated secondary antibody at 4°C for 30 minutes. After washing twice with FACS buffer, the MFI of PE was analyzed using a NovoCyte flow cytometer.

[0152] like Figure 2 As shown in Table 2, all bispecific antibodies bound CHO-K1 cells overexpressing human 4-1BB in a concentration-dependent manner, which was comparable to the parental anti-41BB antibody 263-1-3-1.

[0153] Table 2. Binding affinity to CHO cells overexpressing 4-1BB

[0154] SLC34A2 binding based on cells To evaluate the SLC34A2 binding efficacy of the bispecific antibody, HEK293 cells overexpressing SLC34A2 were incubated with different concentrations of anti-SLC34A2-4-1BB bispecific antibody at 4°C for 30 minutes. The cells were then washed twice with FACS buffer and stained with PE-conjugated secondary antibody at 4°C for 30 minutes. After washing twice with FACS buffer, the MFI of PE was analyzed using a NovoCyte flow cytometer.

[0155] like Figure 3 As shown in Table 3, all bispecific antibodies bound engineered HEK293 cells in a concentration-dependent manner.

[0156] Table 3. Binding affinity to HEK293 cells overexpressing SLC34A2

[0157] SLC34A2 Dependency 4-1BB Activation To evaluate the ability of the anti-SLC34A2-4-1BB bispecific antibody to activate 4-1BB signaling, a reporter gene assay was used. In this assay, Jurkat cells engineered to have surface 4-1BB expression and NF-κB luciferase reporter gene constructs were used as effector cells. HEK293 cells overexpressing SLC34A2 were used as target cells. Briefly, effector cells at a density of 1E5 cells per well and target cells at 1E4 cells per well were co-incubated at 37°C in a 5% CO2 incubator in the presence of 4-fold serially diluted anti-SLC34A2-4-1BB bispecific antibody. After overnight incubation, luminescence was obtained by adding luciferase substrate and measured using a microplate reader.

[0158] like Figure 4 As shown in Table 4, all bispecific antibodies activated SLC34A2-dependent 4-1BB signaling in the presence of target cells.

[0159] Table 4. SLC34A2 Dependence on 4-1BB Signal Transduction

[0160] Example 2. Antigen binding of the lead anti-SLC34A2-4-1BB bispecific antibody This embodiment uses a cell-based assay to evaluate the binding activity of the lead bispecific antibody 30H9-263-1-3-1 in Example 1 against SLC34A2 and 4-1BB, compared with a reference antibody.

[0161] 3.1 Cell-based binding to 4-1BB Using the parental anti-4-1BB antibody 263-1-3-1 as a reference, the in vitro binding of the anti-SLC34A2-4-1BB bispecific antibody 30H9-263-1-3-1 to 4-1BB from different species expressed on the surface of the CHO-K1 cell line was tested.

[0162] like Figure 5 A to Figure 5 As shown in Figure B, the bispecific antibody efficiently binds to CHO-K1 cells overexpressing human cynomolgus / rhesus macaque 4-1BB in a concentration-dependent manner. The estimated mean EC50 of the bispecific antibody was... 50 The 4-1BB titer is 0.56 nM in humans and 1.05 nM in cynomolgus monkeys / rhesus macaques. It is worth noting that, as... Figure 5 C to Figure 5 As shown in D, none of the tested antibodies showed cross-reactivity with mouse 4-1BB and no nonspecific binding activity to blank CHO-K1 cells.

[0163] 3.2 Cell-based binding of SLC34A2 To evaluate antigen-binding properties in a cell-based setting, the binding of 30H9-263-1-3-1 to SLC34A2 overexpressed on HEK293 cells from different species was analyzed by flow cytometry as described above. The parental SLC34A2 monoclonal antibody 30H9 was used as a parallel reference. Figure 6 A to Figure 6 As shown in F, all tested antibodies exhibited typical S-shaped binding behavior against engineered HEK293 cells overexpressing human, cynomolgus monkey, rhesus monkey, rat, and mouse SLC34A2, but showed no non-specific binding activity against blank HEK-293 cells.

[0164] The binding activity against tumor cells expressing endogenous SLC34A2 was also assessed by flow cytometry. Figure 7 A to Figure 7 As shown in B, 30H9-263-1-3-1 binds to OVCAR3 and HCC4006 efficiently in a concentration-dependent manner, with EC50 values ​​of 1.04 nM and 1.49 nM, respectively.

[0165] Example 3. SLC34A2-dependent 4-1BB signaling activation in 4-1BB reporter gene assay This embodiment uses a classic reporter gene assay to investigate the ability of the anti-SLC34A2-4-1BB bispecific antibody 30H9-263-1-3-1 to activate 4-1BB signaling. In this assay, 4-1BB is stably expressed and has NK cells integrated into the genome. Engineered Jurkat cells using the β-luciferase reporter gene construct were used as effector cells. HEK-293 cells engineered to overexpress SLC34A2 and the OVCAR3 tumor cell line endogenously expressing SLC34A2 were used as target cells. Following 4-1BB activation, endogenous NF-β... The B transcription factor binds to DNA reaction elements to induce transcription of the luciferase gene, and the protein product is then quantified by measuring the luminescence signal after substrate addition. In this study, effector cells and target cells were incubated overnight at 37°C with different concentrations of 30H9-263-1-3-1 or a reference antibody in a 5% CO2 incubator. Luciferase substrate was then added, and the luminescence intensity was detected using a microplate reader. Parental anti-4-1BB antibody 263-1-3-1 was used as a control.

[0166] like Figure 8 A to Figure 8 As shown in Figure C, the bispecific antibody 30H9-263-1-3-1 induced significant 4-1BB activation in the presence of target cells expressing SLC34A2. Using human SLC34A2_HEK-293 cells as the target cell line, the estimated EC50 of 30H9-263-1-3-1 was 0.25 nM; using OVCAR3 cells as the target cell line, the estimated EC50 was 0.11 nM. Notably, in the presence of target cells not expressing SLC34A2, 30H9-263-1-3-1 failed to activate 4-1BB signaling, indicating that 30H9-263-1-3-1-mediated 4-1BB activation depends on SLC34A2 binding. In short, HEK293 engineered cells expressing rhesus monkey SLC34A2 (HEK293 / Rhesus_SLC34A2) were incubated together with a chimeric antibody (200 nM, 4-fold dilution, 8 spots). After incubation at 4°C for 60 min, the cells were washed twice with FACS buffer and then stained with a fluorescently conjugated secondary antibody at 4°C for 30 min. The cells were then washed twice and analyzed by flow cytometry.

[0167] Example 4. SLC34A2-dependent primary T cell activation To test the ability of the anti-SLC34A2-4-1BB bispecific antibody 30H9-263-1-3-1 to activate human T cells, human PBMCs (4E5 cells per well) were co-cultured with HEK-293 cells overexpressing SLC34A2 (2E4 cells per well) or OVCAR3 cells in the presence of human anti-CD3 antibody (0.25 μg / mL OKT3) and serially diluted bispecific antibody. After 24 hours of incubation, the IL-2 level in the culture supernatant was measured using a human IL-2 ELISA kit (catalog number Mabtech-3445-1H-20). Simultaneously, after 48 hours of incubation, IFN-γ levels were measured using a human IFN-γ ELISA kit (catalog number Mabtech-3420-1H-20). The level.

[0168] like Figure 9 A to Figure 9 As shown in Figure D, compared to the parental 4-1BB antibody, the SLC34A2-4-1BB bispecific antibody induced significant cytokine production in primary PBMCs in the presence of engineered HEK293 cells. The estimated EC50 of 30H9-263-1-3-1 was... 50 For IL-2, it is 0.55 nM; for IFN- The value was 0.36 nM. Similar results were observed when PBMCs were co-cultured with OVCAR3 cells. In the presence of OVCAR3, the estimated EC50 of 30H9-263-1-3-1 was... 50 For IL-2, it is 0.24 nM; for IFN- It is 0.14 nM.

[0169] Example 5. Tumor growth inhibition (in vivo) of anti-SLC34A2-4-1BB bispecific antibody To evaluate the antitumor efficacy of the anti-SLC34A2-4-1BB bispecific antibody 30H9-263-1-3-1, a syngeneic mouse tumor model was used. This model employed human 4-1BB transgenic mice inoculated with MC38 cells ectopically expressing human SLC34A2. Humanized 4-1BB mice were subcutaneously implanted with 1×102 6 hSLC34A2-MC38 cells. When the average tumor volume grew to 56 mm. 3 Mice bearing tumors were randomly divided into two groups (N=6 / group) and administered the solvent (PBS) and 30H9-263-1-3-1 intraperitoneally, respectively. Antibodies were administered twice weekly. Tumor volume was monitored three times weekly using calipers during the experiment.

[0170] like Figure 10As shown, injection of 30H9-263-1-3-1 produced significant tumor suppression, and all mice in the treatment group were tumor-free approximately one month after the start of treatment. When challenged again with a second dose of the same tumor cells, these tumor-free mice were resistant to tumor re-challenge and were considered tumor-free, while tumor cells continued to grow in untreated mice, indicating that the anti-SLC34A2-4-1BB bispecific antibody 30H9-263-1-3-1 exhibits strong anti-tumor efficacy and induces long-term protective immune memory.

[0171]

[0172] This disclosure is not limited to the specific embodiments described herein, which are intended as a single illustration of various aspects of this disclosure, and any functionally equivalent compositions or methods are within the scope of this disclosure. It will be apparent to those skilled in the art that various modifications and variations can be made to the methods and compositions of this disclosure without departing from the spirit or scope of this disclosure. Therefore, this disclosure is intended to cover such modifications and variations, provided that such modifications and variations are within the scope of the appended claims and their equivalents.

[0173] All publications and patent applications mentioned in this specification are incorporated herein by reference to the extent that each individual publication or patent application is specifically and individually indicated to be incorporated by reference.

Claims

1. A multispecific antibody, said multispecific antibody comprising: (1) The first antibody moiety specifically binds to the human lysosome carrier 34 A2 (SLC34A2) protein, and (2) The second antibody portion that specifically binds to human 4-1BB protein.

2. The multispecific antibody according to claim 1, wherein the multispecific antibody further comprises an Fc domain.

3. The multispecific antibody according to claim 1, wherein the Fc is modified to reduce or eliminate effector function.

4. The multispecific antibody according to any one of claims 1 to 3, wherein the first antibody portion or the second antibody portion is F(ab')2, F(ab)2, Fab', Fab, Fv, scFv or sdAb.

5. The multispecific antibody according to claim 4, wherein the first antibody portion is Fab'.

6. The multispecific antibody according to any one of claims 1 to 5, wherein the second antibody portion is sdAb.

7. The multispecific antibody according to any one of the preceding claims, wherein the Fc domain is derived from any one of the group consisting of IgG1, IgG2, IgG3 and IgG4.

8. The multispecific antibody according to claim 7, wherein the Fc domain is derived from IgG1.

9. The multispecific antibody according to any one of the preceding claims, wherein the first antibody portion is a Fab' fused to the N-terminus of the Fc domain, and the second antibody portion is an sdAb fused to the C-terminus of the Fc domain.

10. The multispecific antibody of claim 9, wherein the second antibody portion is fused to the Fc domain via a linker.

11. The multispecific antibody according to any one of claims 1 to 10, wherein the second antibody portion comprises HCDR1 containing the amino acid SSAMS (SEQ ID NO: 34), HCDR2 containing the amino acid GIYSGGSTYYTESVKD (SEQ ID NO: 35), and HCDR3 containing the amino acid WGTLRFGVWAEYDH (SEQ ID NO: 36).

12. The multispecific antibody of claim 11, wherein the second antibody portion comprises the amino acid sequence of SEQ ID NO: 9 or a peptide having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:

9.

13. The multispecific antibody according to any one of the preceding claims, wherein the first antibody portion comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity-determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises heavy chain complementarity-determining regions LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each comprise the following amino acid sequences: (a) SEQ ID NO: 10 to 15; (b)SEQ ID NO: 16 to 21; (c)SEQ ID NO: 22 to 27, or (d)SEQ ID NO: 28 to 33.

14. The multispecific antibody according to claim 13, wherein the VH and VL of the first antibody portion respectively comprise the following amino acid sequences: (a) SEQ ID NO: 1 and 2; (b) SEQ ID NO: 3 and 4; (c) SEQ ID NO: 5 and 6; or (d)SEQ ID NO: 7 and 8.

15. The multispecific antibody according to any one of claims 2 to 14, wherein the Fc domain comprises an amino acid sequence having at least 80% identity with SEQ ID NO:

37.

16. A composition comprising a multispecific antibody according to any one of claims 1 to 15 and a pharmaceutically acceptable carrier.

17. An isolated cell comprising one or more polynucleotides encoding a multispecific antibody according to any one of claims 1 to 15.

18. A polynucleotide encoding one or more chains of a multispecific antibody according to any one of claims 1 to 15.

19. A method of treating cancer in a patient in need, the method comprising administering to the patient a multispecific antibody according to any one of claims 1 to 15 or a composition according to claim 16.

20. The method of claim 19, further comprising administering a therapy for treating the cancer to the patient.

21. The method of claim 20, wherein the therapy is selected from the group consisting of immunotherapy, chemotherapy and radiotherapy.

22. Use of the multispecific antibody according to any one of claims 1 to 15 or the composition according to claim 16 in the preparation of a medicament for treating cancer in patients in need.

23. The multispecific antibody according to any one of claims 1 to 15 or the composition according to claim 16, for treating cancer in patients in need.

24. The method of any one of claims 19 to 21, or the use according to claim 22, or the use according to claim 23, wherein the cancer is selected from the group consisting of: bladder cancer, liver cancer, colon cancer, rectal cancer, endometrial cancer, leukemia, lymphoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, urethral cancer, head and neck cancer, gastrointestinal cancer, gastric cancer, esophageal cancer, ovarian cancer, kidney cancer, melanoma, prostate cancer, and thyroid cancer.

Citation Information

Patent Citations

  • Production of Bispecific Antibodies

    US20090182127A1

  • Production of Heteromultimeric Proteins

    US20110287009A1

  • Recombinant immunoglobin preparations

    US4816567A

  • Method for making heteromultimeric polypeptides

    US5731168A

  • Production of a single-gene-encoded immunoglobulin

    US5892019A